Abstract
The effect of OP-1206, a prostaglandin E1 derivative, on cauda equina function was analyzed in a model for acute cauda equina compression in the dog. An inflatable balloon was placed under the lamina of the seventh lumbar vertebra in the dog and muscle action potential area (MAP area) and nerve-conduction velocity (NCV) were monitored during 2 h of compression and 1.5 h of recovery. OP-1206 was infused systemically at three concentrations. Only the highest concentration (30 ng/kg/min) of OP-1206 could prevent the reduction in NCV. However, this concentration had no similar effect on the MAP area. The data suggest the potential therapeutic use of prostaglandin E1 analogues for the future treatment of intermittent claudication.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
